Literature DB >> 28335619

Overexpression of the X-Linked Inhibitor of Apoptosis Protects Against Retinal Degeneration in a Feline Model of Retinal Detachment.

Sarah J Wassmer1, Brian C Leonard2,3,4, Stuart G Coupland1,2,3,4, Adam N Baker3, John Hamilton4, William W Hauswirth5, Catherine Tsilfidis1,2,3,4.   

Abstract

Retinal detachment is an acute disorder in humans that is caused by trauma or disease, and it can often lead to permanent visual deficits that result from the death of photoreceptors in the retina. The final pathway for photoreceptor cell death is apoptosis and necroptosis. The X-linked inhibitor of apoptosis (XIAP) has been shown to block both of these cell death pathways. This study tested the effects of XIAP on photoreceptor survival in a feline model of retinal detachment. The study was performed in 12 cats, divided into two experimental groups. Six animals received a subretinal injection of adeno-associated virus (AAV) carrying XIAP, and six animals received AAV carrying green fluorescent protein (GFP) as a control. Three weeks after viral delivery, retinas were detached by injecting C3F8 gas into the subretinal space. Optical coherence tomography revealed that the retinal detachments resolved within 3-6 weeks as the gas was slowly resorbed. Analysis of histological sections through the plane of the detachment showed significant preservation of the photoreceptor layer in AAV-XIAP-treated animals compared to AAV-GFP-treated animals at 9 weeks after the detachment. XIAP-treated detached retinas were similar to intact controls. These studies support the potential for XIAP therapy in the treatment of human retinal detachment.

Entities:  

Keywords:  XIAP; adeno-associated virus; apoptosis; gene therapy; retinal detachment

Mesh:

Substances:

Year:  2017        PMID: 28335619      PMCID: PMC5488383          DOI: 10.1089/hum.2016.161

Source DB:  PubMed          Journal:  Hum Gene Ther        ISSN: 1043-0342            Impact factor:   5.695


  32 in total

1.  Production and purification of recombinant adeno-associated virus.

Authors:  W W Hauswirth; A S Lewin; S Zolotukhin; N Muzyczka
Journal:  Methods Enzymol       Date:  2000       Impact factor: 1.600

2.  FAS-mediated apoptosis and its relation to intrinsic pathway activation in an experimental model of retinal detachment.

Authors:  David N Zacks; Qiong-Duan Zheng; Ying Han; Rita Bakhru; Joan W Miller
Journal:  Invest Ophthalmol Vis Sci       Date:  2004-12       Impact factor: 4.799

3.  Ripoptosome: a novel IAP-regulated cell death-signalling platform.

Authors:  Gergely Imre; Sarit Larisch; Krishnaraj Rajalingam
Journal:  J Mol Cell Biol       Date:  2011-11-23       Impact factor: 6.216

4.  PEG-PLA microparticles for encapsulation and delivery of Tat-EGFP to retinal cells.

Authors:  Mehrdad Rafat; Carolyne A Cléroux; Wai Gin Fong; Adam N Baker; Brian C Leonard; Michael D O'Connor; Catherine Tsilfidis
Journal:  Biomaterials       Date:  2010-02-09       Impact factor: 12.479

5.  Photoreceptor apoptosis in human retinal detachment.

Authors:  Jorge G Arroyo; Liu Yang; Deisy Bula; Dong Feng Chen
Journal:  Am J Ophthalmol       Date:  2005-04       Impact factor: 5.258

6.  Chitosan microparticles for delivery of proteins to the retina.

Authors:  Sarah Wassmer; Mehrdad Rafat; Wai Gin Fong; Adam N Baker; Catherine Tsilfidis
Journal:  Acta Biomater       Date:  2013-04-23       Impact factor: 8.947

7.  Edaravone, an ROS scavenger, ameliorates photoreceptor cell death after experimental retinal detachment.

Authors:  Mi In Roh; Yusuke Murakami; Aristomenis Thanos; Demetrios G Vavvas; Joan W Miller
Journal:  Invest Ophthalmol Vis Sci       Date:  2011-06-01       Impact factor: 4.799

8.  Baculoviral IAP repeat-containing-4 protects optic nerve axons in a rat glaucoma model.

Authors:  Stuart J McKinnon; Donna M Lehman; N Grace Tahzib; Nancy L Ransom; Herbert A Reitsamer; Peter Liston; Eric LaCasse; Qiuhong Li; Robert G Korneluk; William W Hauswirth
Journal:  Mol Ther       Date:  2002-06       Impact factor: 11.454

9.  RIPK3 promotes cell death and NLRP3 inflammasome activation in the absence of MLKL.

Authors:  Kate E Lawlor; Nufail Khan; Alison Mildenhall; Motti Gerlic; Ben A Croker; Akshay A D'Cruz; Cathrine Hall; Sukhdeep Kaur Spall; Holly Anderton; Seth L Masters; Maryam Rashidi; Ian P Wicks; Warren S Alexander; Yasuhiro Mitsuuchi; Christopher A Benetatos; Stephen M Condon; W Wei-Lynn Wong; John Silke; David L Vaux; James E Vince
Journal:  Nat Commun       Date:  2015-02-18       Impact factor: 14.919

10.  Protective effects of resveratrol in experimental retinal detachment.

Authors:  Wei Huang; Guorong Li; Jianming Qiu; Pedro Gonzalez; Pratap Challa
Journal:  PLoS One       Date:  2013-09-11       Impact factor: 3.240

View more
  5 in total

1.  A Drug-Tunable Gene Therapy for Broad-Spectrum Protection against Retinal Degeneration.

Authors:  Clayton P Santiago; Casey J Keuthan; Sanford L Boye; Shannon E Boye; Aisha A Imam; John D Ash
Journal:  Mol Ther       Date:  2018-07-19       Impact factor: 11.454

Review 2.  Caspase-9: A Multimodal Therapeutic Target With Diverse Cellular Expression in Human Disease.

Authors:  Maria I Avrutsky; Carol M Troy
Journal:  Front Pharmacol       Date:  2021-07-09       Impact factor: 5.988

3.  XIAP gene therapy effects on retinal ganglion cell structure and function in a mouse model of glaucoma.

Authors:  Shagana Visuvanathan; Adam N Baker; Pamela S Lagali; Stuart G Coupland; Garfield Miller; William W Hauswirth; Catherine Tsilfidis
Journal:  Gene Ther       Date:  2021-08-06       Impact factor: 5.250

4.  AAV-miR-204 Protects from Retinal Degeneration by Attenuation of Microglia Activation and Photoreceptor Cell Death.

Authors:  Marianthi Karali; Irene Guadagnino; Elena Marrocco; Rossella De Cegli; Annamaria Carissimo; Mariateresa Pizzo; Simona Casarosa; Ivan Conte; Enrico Maria Surace; Sandro Banfi
Journal:  Mol Ther Nucleic Acids       Date:  2019-11-18       Impact factor: 8.886

5.  XIAP Protects Retinal Ganglion Cells in the Mutant ND4 Mouse Model of Leber Hereditary Optic Neuropathy.

Authors:  Sarah J Wassmer; Yves De Repentigny; Derek Sheppard; Pamela S Lagali; Lijun Fang; Stuart G Coupland; Rashmi Kothary; John Guy; William W Hauswirth; Catherine Tsilfidis
Journal:  Invest Ophthalmol Vis Sci       Date:  2020-07-01       Impact factor: 4.799

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.